Moleculin Announces Submission to Expand Clinical Sites in European AML Trial

HOUSTON, June 4, 2020 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that it has submitted requests to Polish regulatory authorities for approval to open two additional clinical sites for its Phase 1/2 clinical study of Annamycin for the treatment of acute myeloid leukemia (“AML”).

The release as fetched from its publisher. moleculin.com ↗